ClinicalTrials.gg
Sign In
CompletedNCT03343886Updated Oct 29, 2026Results posted

Ageing and Health. Spanish Longitudinal Study

An observational study in Health, Subjective, Disability, Evaluation and Chronic Disease, sponsored by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa. Completed at 3 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionMental DisordersRegistry: Chronic DiseaseReclassifiedWhy we changed it
Registry
Chronic Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Mental Disorders
Why
  1. Chronic Disease is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Mental Disorders.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Observational

Updated Oct 29, 2026Now CompletedResults publication added+5 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
7,755
Ages
18 Years and older
Sex
All
01

Study summary

Ageing with Health is a longitudinal cohort study aimed to examine trajectories of health, disability and wellbeing and their determinants for Spanish ageing population. The data that makes up the baseline was collected from a nationally representative sample of non-institutionalized adults as part of the "Collaborative Research on Aging in Europe (COURAGE in Europe)" project between July 2011 and May 2012. The second wave was carried out as part of the "Age with Health" project between December 2014 and June 2015, and three years later, in 2018, the third wave was carried out. In 2019-2021, a new cohort of participants were brought in (2019 cohort), some of whom were interviewed again by telephone during the first Coronavirus (COVID-19) lockdown, in early 2020. In 2022, the fourth wave of the 2011 cohort was evaluated, and in 2023, the second wave of the 2019 cohort was evaluated. Finally, in 2025, the fifth wave of the 2011 cohort and the third wave of the 2019 cohort were evaluated, which are the last follow-ups in this study.

Read the detailed description

Study Design:

A prospective cohort general population study.

Sample:

Wave 1: A nationally representative sample of non-institutionalized adults aged 18 years or older from the Spanish population was collected (with an over-sampling of people aged 50+ years). A multi-stage clustered design was employed; four strata based on the number of inhabitants of the municipalities were built for each of the 17 Spanish autonomous communities. Clusters were selected within the strata with a probability of inclusion relative to their size. Within each cluster, households were randomly selected from a list of all households. In case there was more than one individual from the corresponding age group in the household, a random method was employed to select the individual participant.

Wave 2: Wave 1 sample was re-interviewed (Wave 2) in 2014-2015.

Wave 3: in 2018, participants were again evaluated. Complementarily, between 2019 and 2021 a new sample from the regions of Madrid and Barcelona were brought in, and it was interviewed again by telephone during the first COVID-19 lockdown, in May-June 2020.

Wave 4: a new evaluation of the participants of both cohorts 2011 and 2019 was carried out, in the fist case it terminated in 2022, while the data collection for 2019 cohort terminated in 2023.

Wave 5: the last follow-up of both cohorts was carried out in 2025.

Data collection:

Face-to-face interviews by Computer-Assisted Personal Interviewing at the respondents' homes by trained interviewers. All interviewers received a standardized training. Data quality control was also performed. A proxy interview was administered in those cases in which the participant presents physical or cognitive limitations that may impede the correct administration of the individual interview.

Main project objectives:

To assess trajectories of general health, disability and well-being in Spanish ageing population.

Secondary objectives:

To identify trajectories of healthy ageing (in terms of physical health, mental health, functioning and well-being) in Spanish adult population as well as their determinants To analyse prevalence and impact of chronic health conditions, mental health problems, well-being and loneliness on mortality in Spanish adult population.

To determine risk factors for incidence and persistence of mental and physical health problems in Spanish ageing population.

Main project hypotheses:

The trajectories of health, functioning and well-being will be encompassed by relevant environmental factors such as social support, loneliness and health care utilization, personal factors (socio-demographic characteristics, healthy lifestyles, and high cognitive reserve among others) and other biological and health-related factors (weight, height, waist circumference, executive functions, blood pressure, grip strength, vision acuity, presence of mental and physical health problems and quality of life).

02

Conditions studied

  • Health, Subjective
  • Disability, Evaluation
  • Chronic Disease
  • Mental Disorder
  • Aging
  • Loneliness
  • Cognitive Decline
  • Well-being

Keywords

  • Health Status
  • Well-being
  • Mental Health
  • Risk Factors
  • Aging
03

In context

Mental Disorders Reclassified

1,740 studies on the registry are indexed under Mental Disorders; 348 are open to participants now.

This study's enrollment of 7,755 is above the median of 220 across 389 observational studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa is the lead sponsor of 35 studies on the registry; 6 are open to participants now.

Compared within Mental Disorders, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Chronic Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Community-living individuals in Spain aged 18 years or older

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-institutionalized Spanish residents
  • 18 years and over

Exclusion criteria

Exclusion Criteria:

  • Institutionalized population
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
7,755 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Cohort 2011

    A nationally representative sample of 4753 non-institutionalized adults aged 18 years or older from the Spanish population was collected (with an over-sampling of people aged 50+ years). A multi-stage clustered design was employed. A total of 2528 individuals were re-interviewed in 2014. In 2018, 1577 were again evaluated. In 2022, 963 participants took part of another study's evaluation. The last follow-up of this cohort was conducted in 2025, when 595 participants were evaluated.

  • Cohort 2019

    3002 participants from the regions of Madrid and Barcelona were brought in between 2019 and 2021. The second wave of this cohort was conducted in 2023, and 1,116 participants were evaluated. This cohort was last evaluated in 2025, with 844 participants. In 2020, during the first Coronavirus (COVID-19) lockdown, 1166 of the participants from the first wave of the cohort were telephonically interviewed, a lateral sub-study evaluation.

06

What researchers measure

Primary outcomes

  1. Heath Status

    Measure: Health composite total score. Construct: Health status. Final result: A global total score. Range: 0-100. 0 means lower health status.

    Time frame: Baseline

  2. Disability

    Measure: World Health Organization's Disability Assessment Schedule-II (WHODAS-II). Construct: Disability. Final result: A global total score. Range: 0-100. 0 means lower disability

    Time frame: Baseline

  3. Experienced Well-being

    Abbreviated Version of the Day Reconstruction Method. Construct: Experienced wellbeing. Final Result: The used scale reports two global scores: * Positive Affect total score. Range: 0-100 where 0 means lower positive affect. * Negative Affect total score. Range 0-100 where 0 means lower negative affect.

    Time frame: Baseline

  4. Quality of Life (WHOQOL-AGE)

    Measure: World Health Organization Quality of Life-Age (WHOQOL-AGE) (Caballero, et al., 2013). Construct: Quality of life. Final Result: A global total score. Range 0-100. 0 means lower quality of life

    Time frame: Baseline

Secondary outcomes

  1. Number of Participants With Depression

    Measure: The World Health Organization Composite International Diagnostic Interview (CIDI). Depression module (WHO-CIDI, 1990). Construct: Presence of Depression. Final result: Two measures of depression according to Research Diagnostic Criteria. * Presence of 12 month depression. Values (yes/no). * Presence of lifetime depression. Values (yes/no).

    Time frame: Baseline

  2. Presence of Suicide Behavior

    Measure: The World Health Organization Composite International Diagnostic Interview (CIDI). Suicide module (WHO-CIDI, 1990). Construct: Presence of Suicide behavior The instrument reports six measures of suicide behavior. * Presence of 12 month suicide ideation. Values (yes/no) * Presence of 12 month suicide planning. Values (yes/no) * Presence of 12 month suicide attempts. Values (yes/no) * Presence of lifetime suicide ideation. Values (yes/no) * Presence of lifetime suicide planning. Values (yes/no) * Presence of lifetime suicide attempts. Values (yes/no)

    Time frame: Baseline

  3. Presence of Anxiety Disorders

    Measure: The World Health Organization Composite International Diagnostic Interview (CIDI). Anxiety disorders module (WHO-CIDI, 1990). Construct: Presence of anxiety Disorders Final Result: The instrument included in the study reports six measures of anxiety disorders according to Research diagnostic criteria. * Presence of 12 month panic disorder. Values (yes/no) * Presence of 12 month generalized anxiety disorder. Values (yes/no) * Presence of 12 month phobic disorder. Values (yes/no) * Presence of lifetime panic disorder. Values (yes/no) * Presence of lifetime generalized anxiety disorder. Values (yes/no) * Presence of lifetime phobic disorder. Values (yes/no)

    Time frame: Baseline

  4. Presence of Diabetes

    Construct: Presence of diabetes Measure: Self-reported information of 12-month presence of diagnosis and/or of treatment for diabetes Values: (Yes/No)

    Time frame: Baseline

  5. Presence of Lung Disease

    Construct: Presence of any lung disease Measure: Self-reported information of 12-month presence of diagnosis and/or of treatment for any lung disease Values: (Yes/No)

    Time frame: Baseline

  6. Presence of Stroke

    Construct: Presence of stroke Measure: Self-reported information of 12-month presence of diagnosis and/or of treatment for stroke Values: (Yes/No)

    Time frame: Baseline

Other outcomes

  1. Alcohol Use Information

    Construct: Alcohol use Measure: Self-reported information of how many standard drinks per day in last 7 days have been used. Values: four categories of alcohol use: 0= Lifetime abstainers: Participants that have never used alcohol 1. Occasional drinkers: Participants that have ever used alcohol but not in the previous 7 days 2. Non-heavy drinker: Participants did consume alcohol in the last 30 days and in the last 7 days 3. Infrequent heavy drinker: Participants did consume alcohol 1-2 days per week, with 5 or more standard drinks per day in last 7 days for men and 4 or more standard drinks per day in last 7 days for women. 4. Frequent heavy drinkers: Participants did consume alcohol 3 or more days per week with 5 or more standard drinks per day in last 7 days for men and 4 or more standard drinks per day in last 7 days for women.

    Time frame: Baseline

  2. Tobacco Use Information

    Construct: Tobacco use Measure: Self-reported information of how many cigarettes/pipes/tobacco products/ have been used in the last week. Values: Four categories of tobacco use: 0= Never smokers: Participants who have never used tobacco 1. Daily smokers: Participants who have used tobacco last week 2. Non daily smokers: Participants who have ever used tobacco but not in the previous week 3. Former smokers: Participants who smoked in the past (ex smokers)

    Time frame: Baseline

  3. Level of Physical Activity

    Construct: Level of physical activity Scale: Global Physical Activity Questionnaire version 2 (GPAQ v2); It collects information on physical activity participation in three settings (or domains) and sedentary behavior. The responses given by the participants have been converted to Metabolic Equivalent to Task (MET) values. Applying MET values to activity levels allows for calculating total physical activities. Values: Three values of physical activity can be obtained 3=High physical activity 2=Moderate physical activity 1=Low physical activity

    Time frame: Baseline

  4. Level of Social Support

    Construct: Social Support Measure: 3-Item Oslo Social Support Scale (OSLO) (Abiola et al., 2013) Result: A global total score, then transformed into a percentile scale. Range: 0-100. Higher scores indicate a higher social support.

    Time frame: Baseline

  5. Loneliness

    Construct: Loneliness Measure: Three-item University of California, Los Angeles (UCLA) Loneliness Scale (Hughes et al, 2004) Result: A total loneliness score, then transformed into a percentile scale. Range: 0-100. Higher scores means higher loneliness

    Time frame: Baseline

07

Results

Posted Oct 15, 2024

Participant flow

Spanish general adult population non-institutionalized; aged 18+ years with oversampling of those aged 50+ years and those 80+ years); multi-stage stratified sampling; representative sample.

Participant flow — Overall Study
MilestoneCohort 2011Cohort 2019
Started47533002
Second wave25281037
Third wave1577844
Fourth wave9630
Fifth wave5950
Completed595844
Not completed41582158

Outcome measures

PrimaryHeath Status

Measure: Health composite total score. Construct: Health status. Final result: A global total score. Range: 0-100. 0 means lower health status.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Heath Status
score on a scaleCohort 2011Cohort 2019
Heath Status66.55 ± 13.1168.95 ± 19.87
PrimaryDisability

Measure: World Health Organization's Disability Assessment Schedule-II (WHODAS-II). Construct: Disability. Final result: A global total score. Range: 0-100. 0 means lower disability

Time frame:
Baseline
Reported as:
Mean · score on a scale
Disability
score on a scaleCohort 2011 Sample Demographic CharacteristicsCohort 2019 Sample Demographic Characteristics
Disability11.17 ± 17.599.01 ± 18.20
PrimaryExperienced Well-being

Abbreviated Version of the Day Reconstruction Method. Construct: Experienced wellbeing. Final Result: The used scale reports two global scores: * Positive Affect total score. Range: 0-100 where 0 means lower positive affect. * Negative Affect total score. Range 0-100 where 0 means lower negative affect.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Experienced Well-being
score on a scaleCohort 2011Cohort 2019
Positive Affect4.88 ± 1.114.75 ± 1.59
Negative Affect0.64 ± 0.890.33 ± 0.61
PrimaryQuality of Life (WHOQOL-AGE)

Measure: World Health Organization Quality of Life-Age (WHOQOL-AGE) (Caballero, et al., 2013). Construct: Quality of life. Final Result: A global total score. Range 0-100. 0 means lower quality of life

Time frame:
Baseline
Reported as:
Mean · score on a scale
Quality of Life (WHOQOL-AGE)
score on a scaleCohort 2011Cohort 2019
Quality of Life (WHOQOL-AGE)72.30 ± 14.9076.17 ± 15.25
SecondaryNumber of Participants With Depression

Measure: The World Health Organization Composite International Diagnostic Interview (CIDI). Depression module (WHO-CIDI, 1990). Construct: Presence of Depression. Final result: Two measures of depression according to Research Diagnostic Criteria. * Presence of 12 month depression. Values (yes/no). * Presence of lifetime depression. Values (yes/no).

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants With Depression
ParticipantsCohort 2011Cohort 2019
Number of Participants With Depression510203
SecondaryPresence of Suicide Behavior

Measure: The World Health Organization Composite International Diagnostic Interview (CIDI). Suicide module (WHO-CIDI, 1990). Construct: Presence of Suicide behavior The instrument reports six measures of suicide behavior. * Presence of 12 month suicide ideation. Values (yes/no) * Presence of 12 month suicide planning. Values (yes/no) * Presence of 12 month suicide attempts. Values (yes/no) * Presence of lifetime suicide ideation. Values (yes/no) * Presence of lifetime suicide planning. Values (yes/no) * Presence of lifetime suicide attempts. Values (yes/no)

Time frame:
Baseline
Reported as:
Count of participants · Participants
Presence of Suicide Behavior
ParticipantsCohort 2011Cohort 2019
Presence of Suicide Behavior16175
SecondaryPresence of Anxiety Disorders

Measure: The World Health Organization Composite International Diagnostic Interview (CIDI). Anxiety disorders module (WHO-CIDI, 1990). Construct: Presence of anxiety Disorders Final Result: The instrument included in the study reports six measures of anxiety disorders according to Research diagnostic criteria. * Presence of 12 month panic disorder. Values (yes/no) * Presence of 12 month generalized anxiety disorder. Values (yes/no) * Presence of 12 month phobic disorder. Values (yes/no) * Presence of lifetime panic disorder. Values (yes/no) * Presence of lifetime generalized anxiety disorder. Values (yes/no) * Presence of lifetime phobic disorder. Values (yes/no)

Time frame:
Baseline
Reported as:
Count of participants · Participants
Presence of Anxiety Disorders
ParticipantsCohort 2011Cohort 2019
Presence of Anxiety Disorders6977
SecondaryPresence of Diabetes

Construct: Presence of diabetes Measure: Self-reported information of 12-month presence of diagnosis and/or of treatment for diabetes Values: (Yes/No)

Time frame:
Baseline
Reported as:
Count of participants · Participants
Presence of Diabetes
ParticipantsCohort 2011Cohort 2019
Presence of Diabetes661353
SecondaryPresence of Lung Disease

Construct: Presence of any lung disease Measure: Self-reported information of 12-month presence of diagnosis and/or of treatment for any lung disease Values: (Yes/No)

Time frame:
Baseline
Reported as:
Count of participants · Participants
Presence of Lung Disease
ParticipantsCohort 2011Cohort 2019
Presence of Lung Disease399152
SecondaryPresence of Stroke

Construct: Presence of stroke Measure: Self-reported information of 12-month presence of diagnosis and/or of treatment for stroke Values: (Yes/No)

Time frame:
Baseline
Reported as:
Count of participants · Participants
Presence of Stroke
ParticipantsCohort 2011Cohort 2019
Presence of Stroke18382
Other pre-specifiedAlcohol Use Information

Construct: Alcohol use Measure: Self-reported information of how many standard drinks per day in last 7 days have been used. Values: four categories of alcohol use: 0= Lifetime abstainers: Participants that have never used alcohol 1. Occasional drinkers: Participants that have ever used alcohol but not in the previous 7 days 2. Non-heavy drinker: Participants did consume alcohol in the last 30 days and in the last 7 days 3. Infrequent heavy drinker: Participants did consume alcohol 1-2 days per week, with 5 or more standard drinks per day in last 7 days for men and 4 or more standard drinks per day in last 7 days for women. 4. Frequent heavy drinkers: Participants did consume alcohol 3 or more days per week with 5 or more standard drinks per day in last 7 days for men and 4 or more standard drinks per day in last 7 days for women.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Alcohol Use Information
ParticipantsCohort 2011Cohort 2019
Lifetime abstainers1345871
Occasional drinkers14241055
Non-heavy drinker1671846
Infrequent heavy drinker11195
Frequent heavy drinker3238
Missing06
Other pre-specifiedTobacco Use Information

Construct: Tobacco use Measure: Self-reported information of how many cigarettes/pipes/tobacco products/ have been used in the last week. Values: Four categories of tobacco use: 0= Never smokers: Participants who have never used tobacco 1. Daily smokers: Participants who have used tobacco last week 2. Non daily smokers: Participants who have ever used tobacco but not in the previous week 3. Former smokers: Participants who smoked in the past (ex smokers)

Time frame:
Baseline
Reported as:
Count of participants · Participants
Tobacco Use Information
ParticipantsCohort 2011Cohort 2019
Never smokers23391543
Daily smokers1049626
Non daily smokers10052
Former smokers1095690
Other pre-specifiedLevel of Physical Activity

Construct: Level of physical activity Scale: Global Physical Activity Questionnaire version 2 (GPAQ v2); It collects information on physical activity participation in three settings (or domains) and sedentary behavior. The responses given by the participants have been converted to Metabolic Equivalent to Task (MET) values. Applying MET values to activity levels allows for calculating total physical activities. Values: Three values of physical activity can be obtained 3=High physical activity 2=Moderate physical activity 1=Low physical activity

Time frame:
Baseline
Reported as:
Count of participants · Participants
Level of Physical Activity
ParticipantsCohort 2011Cohort 2019
High1464898
Moderate17241013
Low1395991
Other pre-specifiedLevel of Social Support

Construct: Social Support Measure: 3-Item Oslo Social Support Scale (OSLO) (Abiola et al., 2013) Result: A global total score, then transformed into a percentile scale. Range: 0-100. Higher scores indicate a higher social support.

Time frame:
Baseline
Reported as:
Mean · score on a scale
Level of Social Support
score on a scaleCohort 2011Cohort 2019
Level of Social Support77.50 ± 16.7377.44 ± 17.70
Other pre-specifiedLoneliness

Construct: Loneliness Measure: Three-item University of California, Los Angeles (UCLA) Loneliness Scale (Hughes et al, 2004) Result: A total loneliness score, then transformed into a percentile scale. Range: 0-100. Higher scores means higher loneliness

Time frame:
Baseline
Reported as:
Mean · score on a scale
Loneliness
score on a scaleCohort 2011Cohort 2019
Loneliness12.34 ± 24.2510.74 ± 22.82

Adverse events

Collected over For both cohorts (2011 and 2019), data on adverse events and deaths are collected at the same time, when a new wave is carried out. Specifically for cohort 2011 adverse events have been evaluated 4 times during 12 years (2011-2012, 2014-2015, 2019-2021 and 2022-2023) and for cohort 2019 they have been evaluated 2 times during 4 years (2019-2020 and 2022-2023).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 2011591/4,753 (12.4%)706/4,753 (14.9%)1,447/4,753 (30.4%)
Cohort 2019157/3,002 (5.2%)234/3,002 (7.8%)1,474/3,002 (49.1%)
Most frequent serious events
Most frequent serious events
EventCohort 2011Cohort 2019
Lungs problemsRespiratory, thoracic and mediastinal disorders426/4753152/3002
StrokeVascular disorders280/475382/3002
Most frequent other events
Most frequent other events
EventCohort 2011Cohort 2019
ArthritisMusculoskeletal and connective tissue disorders808/4753794/3002
DiabetesMetabolism and nutrition disorders325/4753353/3002
CataractEye disorders314/4753327/3002

Baseline characteristics

At the baseline, 4,753 participants were interviewed (2011 cohort) and in 2019-2021 3,002 participants were brought in (2019 cohort).

Age, Categorical
Age, Categorical(Participants)Cohort 2011 Sample Demographic CharacteristicsCohort 2019 Sample Demographic CharacteristicsTotal
<=18 years000
Between 18 and 65 years274218674609
>=65 years201111353146
Age, Continuous
Age, Continuous(years)Cohort 2011 Sample Demographic CharacteristicsCohort 2019 Sample Demographic CharacteristicsTotal
Mean60.44 ± 16.2458.19 ± 17.8959.32 ± 17.07
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 2011 Sample Demographic CharacteristicsCohort 2019 Sample Demographic CharacteristicsTotal
Female260213023904
Male215117003851
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 2011 Sample Demographic CharacteristicsCohort 2019 Sample Demographic CharacteristicsTotal
Hispanic or Latino475330027755
Not Hispanic or Latino000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Cohort 2011 Sample Demographic CharacteristicsCohort 2019 Sample Demographic CharacteristicsTotal
Spain475330027755
Education
Education(Participants)Cohort 2011 Sample Demographic CharacteristicsCohort 2019 Sample Demographic CharacteristicsTotal
No education373100473
Less than primary10013531354
Primary13067612067
Secondary562428990
High School8747241598
University+5724601032
Post graduate degree64175239
Missing data112
Marital status
Marital status(Participants)Cohort 2011 Sample Demographic CharacteristicsCohort 2019 Sample Demographic CharacteristicsTotal
Single6804951175
Married267016664336
Cohabiting175127302
Separated/divorced346306652
Widowed8824081290
Health Status
Health Status(units on a scale)Cohort 2011 Sample Demographic CharacteristicsCohort 2019 Sample Demographic CharacteristicsTotal
Mean66.55 ± 13.1168.95 ± 19.8767.75 ± 16.49
08

Study locations

3 sites
  • Fundació Sant Joan de Déu
    Sant Boi de Llobregat, Barcelona 08830, Spain
  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
    Madrid, Madrid 28006, Spain
  • Universidad Autónoma de Madrid
    Madrid, Madrid 28029, Spain
09

References and documents

Publications

  • Gabarrell-Pascuet A, Varga TV, Moneta MV, Ayuso-Mateos JL, Lara E, Olaya B, Haro JM, Domenech-Abella J. What factors explain the changes in major depressive disorder symptoms by age group during the COVID-19 pandemic? A longitudinal study. J Affect Disord. 2023 May 1;328:72-80. doi: 10.1016/j.jad.2023.02.042. Epub 2023 Feb 16. PubMed 36806591 ↗
  • Bayes-Marin I, Fernandez D, Lara E, Martin-Maria N, Miret M, Moreno-Agostino D, Ayuso-Mateos JL, Sanchez-Niubo A, Haro JM, Olaya B. Trajectories of Immediate and Delayed Verbal Memory in the Spanish General Population of Middle-aged and Older Adults. Brain Sci. 2020 Apr 22;10(4):249. doi: 10.3390/brainsci10040249. PubMed 32331406 ↗
  • Olaya B, Moneta MV, Lara E, Miret M, Martin-Maria N, Moreno-Agostino D, Ayuso-Mateos JL, Abduljabbar AS, Haro JM. Fruit and Vegetable Consumption and Potential Moderators Associated with All-Cause Mortality in a Representative Sample of Spanish Older Adults. Nutrients. 2019 Aug 2;11(8):1794. doi: 10.3390/nu11081794. PubMed 31382535 ↗
  • Moreno-Agostino, D., de la Torre-Luque, A., de la Fuente, J., Lara, E., Martín-María, N., Moneta, M. V., … & Ayuso-Mateos, J. L. (2020). Determinants of Subjective Wellbeing Trajectories in Older Adults: A Growth Mixture Modeling Approach. Journal of Happiness Studies, 1-18.
  • Martin-Maria N, Caballero FF, Miret M, Tyrovolas S, Haro JM, Ayuso-Mateos JL, Chatterji S. Differential impact of transient and chronic loneliness on health status. A longitudinal study. Psychol Health. 2020 Feb;35(2):177-195. doi: 10.1080/08870446.2019.1632312. Epub 2019 Jun 25. PubMed 31237442 ↗
  • Lara E, Moreno-Agostino D, Martin-Maria N, Miret M, Rico-Uribe LA, Olaya B, Cabello M, Haro JM, Ayuso-Mateos JL. Exploring the effect of loneliness on all-cause mortality: Are there differences between older adults and younger and middle-aged adults? Soc Sci Med. 2020 Aug;258:113087. doi: 10.1016/j.socscimed.2020.113087. Epub 2020 May 30. PubMed 32554229 ↗
  • Gayete S, Gine A, Miret M, Ayuso-Mateos JL, Haro JM, Olaya B. Cognitive function associated with different diagnoses of anxiety disorders over the lifespan: Results from a Spanish representative sample. J Anxiety Disord. 2020 Oct;75:102296. doi: 10.1016/j.janxdis.2020.102296. Epub 2020 Aug 20. PubMed 32866758 ↗
  • Martin-Maria N, Caballero FF, Lara E, Domenech-Abella J, Haro JM, Olaya B, Ayuso-Mateos JL, Miret M. Effects of transient and chronic loneliness on major depression in older adults: A longitudinal study. Int J Geriatr Psychiatry. 2021 Jan;36(1):76-85. doi: 10.1002/gps.5397. Epub 2020 Sep 10. PubMed 32791563 ↗
  • Garcia-Esquinas E, Ortola R, Gine-Vazquez I, Carnicero JA, Manas A, Lara E, Alvarez-Bustos A, Vicente-Rodriguez G, Sotos-Prieto M, Olaya B, Garcia-Garcia FJ, Gusi N, Banegas JR, Rodriguez-Gomez I, Struijk EA, Martinez-Gomez D, Lana A, Haro JM, Ayuso-Mateos JL, Rodriguez-Manas L, Ara I, Miret M, Rodriguez-Artalejo F. Changes in Health Behaviors, Mental and Physical Health among Older Adults under Severe Lockdown Restrictions during the COVID-19 Pandemic in Spain. Int J Environ Res Public Health. 2021 Jul 1;18(13):7067. doi: 10.3390/ijerph18137067. PubMed 34281004 ↗
  • Gabarrell-Pascuet A, Moneta MV, Ayuso-Mateos JL, Miret M, Lara E, Haro JM, Olaya B, Domenech-Abella J. The effect of loneliness and social support on the course of major depressive disorder among adults aged 50 years and older: A longitudinal study. Depress Anxiety. 2022 Feb;39(2):147-155. doi: 10.1002/da.23236. Epub 2022 Jan 14. PubMed 35029840 ↗
  • Rodeiro, J., Olaya, B., Haro, J. M., Gabarrell-Pascuet, A., Ayuso-Mateos, J. L., Francia, L., … & Domènech-Abella, J. (2025). The longitudinal relationship among physical activity, loneliness, and mental health in middle-aged and older adults: Results from the Edad con Salud cohort. Mental Health and Physical Activity, 100667.
  • Francia L, De Giorgi R, Lara E, Del Castellar BD, Castelletti C, Rodriguez-Prada C, Domenech-Abella J, Olaya B, Haro JM, Ayuso Mateos JL. Treatment coverage for depression in the general Spanish population and the impact of the Covid-19 pandemic. Heliyon. 2024 Jun 8;10(11):e32594. doi: 10.1016/j.heliyon.2024.e32594. eCollection 2024 Jun 15. PubMed 38961986 ↗
  • Zhang Z, Domenech-Abella J, Rodeiro-Boliart J, Gete-Alejandro I, Ayuso-Mateos JL, Miret M, Perez EL, Godino-Cruz J, Haro JM, Olaya B. The impact of physical multimorbidity on common mental disorders and the role of loneliness and social support: A three-year follow-up study. J Affect Disord. 2026 Aug 15;407:121795. doi: 10.1016/j.jad.2026.121795. Epub 2026 Apr 13. PubMed 41985760 ↗
  • Rodriguez-Prada C, Cabello M, Caballero FF, Dolz-Del-Castellar B, Francia L, Miret M, Haro JM, Domenech-Abella J, Olaya B, Ayuso-Mateos JL. Analyzing the Impact of Depression on All-Cause Mortality in Different Sex and Age Groups: A 11-Year Follow-Up Study of Spanish Population. Int J Soc Psychiatry. 2026 Mar 22:207640261430311. doi: 10.1177/00207640261430311. Online ahead of print. PubMed 41865302 ↗
  • Longo V, Domenech-Abella J, Gete-Alejandro I, Ayuso-Mateos JL, Miret M, Godino-Cruz J, Lara E, Cristobal-Narvaez P, Haro JM. The association between loneliness and suicide ideation: A cross-sectional comparison of Latin American immigrants and Spanish natives in Spain. J Affect Disord. 2026 Aug 1;406:121347. doi: 10.1016/j.jad.2026.121347. Epub 2026 Feb 5. PubMed 41653995 ↗
  • Godino-Cruz, J., Martín-María, N., Lara, E., Olaya, B., Domènech-Abella, J., Haro, J. M., … & Miret, M. (2026). Unveiling the Importance of Eudaimonia: a Longitudinal Study of Subjective well-being and Disability. Applied Research in Quality of Life, 1-16.
  • Domenech-Abella J, Muntaner C, Rodeiro J, Gabarrell-Pascuet A, Haro JM, Ayuso-Mateos JL, Miret M, Olaya B. The association of material deprivation with major depressive disorder and the role of loneliness and social support: A cross-sectional study. J Affect Disord. 2025 Jan 1;368:172-179. doi: 10.1016/j.jad.2024.09.071. Epub 2024 Sep 13. PubMed 39278471 ↗
  • Moreno-Agostino D, Caballero FF, Martin-Maria N, Tyrovolas S, Lopez-Garcia P, Rodriguez-Artalejo F, Haro JM, Ayuso-Mateos JL, Miret M. Mediterranean diet and wellbeing: evidence from a nationwide survey. Psychol Health. 2019 Mar;34(3):321-335. doi: 10.1080/08870446.2018.1525492. Epub 2018 Oct 15. PubMed 30320519 ↗
  • Lara E, Miret M, Olaya B, Caballero FF, Morillo D, Moneta MV, Haro JM, Ayuso-Mateos JL. Cohort Profile: The Spanish Longitudinal Study on Ageing and Health (Edad Con Salud). Int J Epidemiol. 2022 Aug 10;51(4):e189-e199. doi: 10.1093/ije/dyac118. No abstract available. PubMed 35712861 ↗
  • Olaya B, de Miquel C, Francia L, Rodriguez-Prada C, Dolz Del Castellar B, Ayuso-Mateos JL, Haro JM, Domenech-Abella J. Understanding the incidence and recurrence of depression and associated risk factors in 9 years of follow-up: Results from a population-based sample. Psychiatry Res. 2025 Mar;345:116375. doi: 10.1016/j.psychres.2025.116375. Epub 2025 Jan 24. PubMed 39893856 ↗
  • Francia L, Miret M, Lara E, Dolz Del Castellar B, Domenech-Abella J, Olaya B, Haro JM, Cuadrado DM, Ayuso Mateos JL. Impact of the changes from ICD-10 to ICD-11 in the diagnosis of depressive disorder in the general population. J Psychiatr Res. 2025 Apr;184:367-370. doi: 10.1016/j.jpsychires.2025.03.012. Epub 2025 Mar 12. PubMed 40088592 ↗
  • Dolz-Del-Castellar B, de la Torre-Luque A, Castelletti C, Francia L, Rodriguez-Prada C, Miret M, Domenech-Abella J, Gabarrell-Pascuet A, Olaya B, Haro JM, Ayuso-Mateos JL, Lara E. Loneliness trajectories and predictors in Spain: Results from the Spanish longitudinal study on aging and health (Edad con Salud). J Affect Disord. 2025 Jun 1;378:100-108. doi: 10.1016/j.jad.2025.02.084. Epub 2025 Feb 25. PubMed 40015651 ↗
  • Izquierdo A, Dolz-Del-Castellar B, Miret M, Olaya B, Haro JM, Ayuso-Mateos JL, Lara E. Sex differences in the symptom network structure of depression: Findings from a nationwide sample of the Spanish adult population. J Affect Disord. 2023 Nov 1;340:583-591. doi: 10.1016/j.jad.2023.08.081. Epub 2023 Aug 15. PubMed 37591351 ↗
  • Miret M, Caballero FF, Olaya B, Koskinen S, Naidoo N, Tobiasz-Adamczyk B, Leonardi M, Haro JM, Chatterji S, Ayuso-Mateos JL. Association of experienced and evaluative well-being with health in nine countries with different income levels: a cross-sectional study. Global Health. 2017 Aug 23;13(1):65. doi: 10.1186/s12992-017-0290-0. PubMed 28835255 ↗
  • Olaya B, Moneta MV, Domenech-Abella J, Miret M, Bayes I, Ayuso-Mateos JL, Haro JM. Mobility Difficulties, Physical Activity, and All-cause Mortality Risk in a Nationally representative Sample of Older Adults. J Gerontol A Biol Sci Med Sci. 2018 Aug 10;73(9):1272-1279. doi: 10.1093/gerona/glx121. PubMed 28633439 ↗
  • Lara E, Koyanagi A, Domenech-Abella J, Miret M, Ayuso-Mateos JL, Haro JM. The Impact of Depression on the Development of Mild Cognitive Impairment over 3 Years of Follow-Up: A Population-Based Study. Dement Geriatr Cogn Disord. 2017;43(3-4):155-169. doi: 10.1159/000455227. Epub 2017 Feb 9. PubMed 28178703 ↗
  • Martin-Maria N, Miret M, Caballero FF, Rico-Uribe LA, Steptoe A, Chatterji S, Ayuso-Mateos JL. The Impact of Subjective Well-being on Mortality: A Meta-Analysis of Longitudinal Studies in the General Population. Psychosom Med. 2017 Jun;79(5):565-575. doi: 10.1097/PSY.0000000000000444. PubMed 28033196 ↗
  • Lara E, Koyanagi A, Caballero F, Domenech-Abella J, Miret M, Olaya B, Rico-Uribe L, Ayuso-Mateos JL, Haro JM. Cognitive reserve is associated with quality of life: A population-based study. Exp Gerontol. 2017 Jan;87(Pt A):67-73. doi: 10.1016/j.exger.2016.10.012. Epub 2016 Nov 5. PubMed 27825839 ↗
  • Kamenov K, Caballero FF, Miret M, Leonardi M, Sainio P, Tobiasz-Adamczyk B, Haro JM, Chatterji S, Ayuso-Mateos JL, Cabello M. Which Are the Most Burdensome Functioning Areas in Depression? A Cross-National Study. Front Psychol. 2016 Aug 31;7:1342. doi: 10.3389/fpsyg.2016.01342. eCollection 2016. PubMed 27630609 ↗
  • Martin-Maria N, Caballero FF, Olaya B, Rodriguez-Artalejo F, Haro JM, Miret M, Ayuso-Mateos JL. Positive Affect Is Inversely Associated with Mortality in Individuals without Depression. Front Psychol. 2016 Jul 12;7:1040. doi: 10.3389/fpsyg.2016.01040. eCollection 2016. PubMed 27462289 ↗
  • Raggi A, Corso B, Minicuci N, Quintas R, Sattin D, De Torres L, Chatterji S, Frisoni GB, Haro JM, Koskinen S, Martinuzzi A, Miret M, Tobiasz-Adamczyk B, Leonardi M. Determinants of Quality of Life in Ageing Populations: Results from a Cross-Sectional Study in Finland, Poland and Spain. PLoS One. 2016 Jul 19;11(7):e0159293. doi: 10.1371/journal.pone.0159293. eCollection 2016. PubMed 27434374 ↗
  • Tyrovolas S, Koyanagi A, Olaya B, Ayuso-Mateos JL, Miret M, Chatterji S, Tobiasz-Adamczyk B, Koskinen S, Leonardi M, Haro JM. Factors associated with skeletal muscle mass, sarcopenia, and sarcopenic obesity in older adults: a multi-continent study. J Cachexia Sarcopenia Muscle. 2016 Jun;7(3):312-21. doi: 10.1002/jcsm.12076. Epub 2015 Oct 7. PubMed 27239412 ↗
  • Lara E, Koyanagi A, Olaya B, Lobo A, Miret M, Tyrovolas S, Ayuso-Mateos JL, Haro JM. Mild cognitive impairment in a Spanish representative sample: prevalence and associated factors. Int J Geriatr Psychiatry. 2016 Aug;31(8):858-67. doi: 10.1002/gps.4398. Epub 2016 Feb 28. PubMed 26923809 ↗
  • Olaya B, Moneta MV, Koyanagi A, Lara E, Miret M, Ayuso-Mateos JL, Chatterji S, Leonardi M, Koskinen S, Tobiasz-Adamczyk B, Lobo A, Haro JM. The joint association of depression and cognitive function with severe disability among community-dwelling older adults in Finland, Poland and Spain. Exp Gerontol. 2016 Apr;76:39-45. doi: 10.1016/j.exger.2016.01.010. Epub 2016 Jan 22. PubMed 26805608 ↗
  • Rico-Uribe LA, Caballero FF, Olaya B, Tobiasz-Adamczyk B, Koskinen S, Leonardi M, Haro JM, Chatterji S, Ayuso-Mateos JL, Miret M. Loneliness, Social Networks, and Health: A Cross-Sectional Study in Three Countries. PLoS One. 2016 Jan 13;11(1):e0145264. doi: 10.1371/journal.pone.0145264. eCollection 2016. PubMed 26761205 ↗
  • Tyrovolas S, Koyanagi A, Olaya B, Ayuso-Mateos JL, Miret M, Chatterji S, Tobiasz-Adamczyk B, Koskinen S, Leonardi M, Haro JM. The role of muscle mass and body fat on disability among older adults: A cross-national analysis. Exp Gerontol. 2015 Sep;69:27-35. doi: 10.1016/j.exger.2015.06.002. Epub 2015 Jun 3. PubMed 26048566 ↗
  • Koyanagi A, Stickley A, Garin N, Miret M, Ayuso-Mateos JL, Leonardi M, Koskinen S, Galas A, Haro JM. The association between obesity and back pain in nine countries: a cross-sectional study. BMC Public Health. 2015 Feb 11;15:123. doi: 10.1186/s12889-015-1362-9. PubMed 25886589 ↗
  • Tyrovolas S, Koyanagi A, Garin N, Olaya B, Ayuso-Mateos JL, Miret M, Chatterji S, Tobiasz-Adamczyk B, Koskinen S, Leonardi M, Haro JM. Diabetes mellitus and its association with central obesity and disability among older adults: a global perspective. Exp Gerontol. 2015 Apr;64:70-7. doi: 10.1016/j.exger.2015.02.010. Epub 2015 Feb 16. PubMed 25688991 ↗
  • Tyrovolas S, Koyanagi A, Garin N, Olaya B, Ayuso-Mateos JL, Miret M, Chatterji S, Tobiasz-Adamczyk B, Koskinen S, Leonardi M, Haro JM. Determinants of the components of arterial pressure among older adults--the role of anthropometric and clinical factors: a multi-continent study. Atherosclerosis. 2015 Feb;238(2):240-9. doi: 10.1016/j.atherosclerosis.2014.11.029. Epub 2014 Dec 9. PubMed 25528433 ↗
  • Miret M, Caballero FF, Chatterji S, Olaya B, Tobiasz-Adamczyk B, Koskinen S, Leonardi M, Haro JM, Ayuso-Mateos JL. Health and happiness: cross-sectional household surveys in Finland, Poland and Spain. Bull World Health Organ. 2014 Oct 1;92(10):716-25. doi: 10.2471/BLT.13.129254. Epub 2014 Aug 13. PubMed 25378725 ↗
  • Garin N, Olaya B, Moneta MV, Miret M, Lobo A, Ayuso-Mateos JL, Haro JM. Impact of multimorbidity on disability and quality of life in the Spanish older population. PLoS One. 2014 Nov 6;9(11):e111498. doi: 10.1371/journal.pone.0111498. eCollection 2014. PubMed 25375890 ↗
  • Garin N, Olaya B, Miret M, Ayuso-Mateos JL, Power M, Bucciarelli P, Haro JM. Built environment and elderly population health: a comprehensive literature review. Clin Pract Epidemiol Ment Health. 2014 Oct 21;10:103-15. doi: 10.2174/1745017901410010103. eCollection 2014. PubMed 25356084 ↗
  • Lara E, Olaya B, Garin N, Ayuso-Mateos JL, Miret M, Moneta V, Haro JM. Is cognitive impairment associated with suicidality? A population-based study. Eur Neuropsychopharmacol. 2015 Feb;25(2):203-13. doi: 10.1016/j.euroneuro.2014.08.010. Epub 2014 Aug 21. PubMed 25190638 ↗
  • Garin N, Olaya B, Lara E, Moneta MV, Miret M, Ayuso-Mateos JL, Haro JM. Visual impairment and multimorbidity in a representative sample of the Spanish population. BMC Public Health. 2014 Aug 8;14:815. doi: 10.1186/1471-2458-14-815. PubMed 25103270 ↗
  • Miret M, Caballero FF, Huerta-Ramirez R, Moneta MV, Olaya B, Chatterji S, Haro JM, Ayuso-Mateos JL. Factors associated with suicidal ideation and attempts in Spain for different age groups. Prevalence before and after the onset of the economic crisis. J Affect Disord. 2014 Jul;163:1-9. doi: 10.1016/j.jad.2014.03.045. Epub 2014 Apr 1. PubMed 24836081 ↗
  • Quintas R, Raggi A, Bucciarelli P, Franco MG, Andreotti A, Caballero FF, Olaya B, Chatterji S, Galas A, Merilainen-Porras S, Frisoni G, Russo E, Minicuci N, Power M, Leonardi M. The COURAGE Built Environment Outdoor Checklist: an objective built environment instrument to investigate the impact of the environment on health and disability. Clin Psychol Psychother. 2014 May-Jun;21(3):204-14. doi: 10.1002/cpp.1858. Epub 2013 Jul 29. PubMed 23897864 ↗
  • Leonardi M, Chatterji S, Koskinen S, Ayuso-Mateos JL, Haro JM, Frisoni G, Frattura L, Martinuzzi A, Tobiasz-Adamczyk B, Gmurek M, Serrano R, Finocchiaro C; COURAGE in Europe Project's Consortium. Determinants of health and disability in ageing population: the COURAGE in Europe Project (collaborative research on ageing in Europe). Clin Psychol Psychother. 2014 May-Jun;21(3):193-8. doi: 10.1002/cpp.1856. Epub 2013 Jul 24. PubMed 23881690 ↗
  • Perales J, Martin S, Ayuso-Mateos JL, Chatterji S, Garin N, Koskinen S, Leonardi M, Miret M, Moneta V, Olaya B, Tobiasz-Adamczyk B, Haro JM. Factors associated with active aging in Finland, Poland, and Spain. Int Psychogeriatr. 2014 Aug;26(8):1363-75. doi: 10.1017/S1041610214000520. Epub 2014 Apr 15. PubMed 24735743 ↗
  • Garin N, Olaya B, Perales J, Moneta MV, Miret M, Ayuso-Mateos JL, Haro JM. Multimorbidity patterns in a national representative sample of the Spanish adult population. PLoS One. 2014 Jan 20;9(1):e84794. doi: 10.1371/journal.pone.0084794. eCollection 2014. PubMed 24465433 ↗
  • Caballero FF, Miret M, Power M, Chatterji S, Tobiasz-Adamczyk B, Koskinen S, Leonardi M, Olaya B, Haro JM, Ayuso-Mateos JL. Validation of an instrument to evaluate quality of life in the aging population: WHOQOL-AGE. Health Qual Life Outcomes. 2013 Oct 23;11:177. doi: 10.1186/1477-7525-11-177. PubMed 24152691 ↗
  • Zawisza K, Galas A, Tobiasz-Adamczyk B, Chatterji S, Haro JM, Miret M, Koskinen S, Power M, Leonardi M. The validity of the instrument to evaluate social network in the ageing population: the Collaborative Research on Ageing in Europe Social Network Index. Clin Psychol Psychother. 2014 May-Jun;21(3):227-41. doi: 10.1002/cpp.1860. Epub 2013 Aug 12. PubMed 23939715 ↗
  • Raggi A, Quintas R, Bucciarelli P, Franco MG, Andreotti A, Miret M, Zawisza K, Olaya B, Chatterji S, Sainio P, Frisoni GB, Martinuzzi A, Minicuci N, Power M, Leonardi M. Validation of the COURAGE Built Environment Self-Reported Questionnaire. Clin Psychol Psychother. 2014 May-Jun;21(3):215-26. doi: 10.1002/cpp.1859. Epub 2013 Jul 16. PubMed 23861306 ↗
  • Raggi A, Quintas R, Russo E, Martinuzzi A, Costardi D, Frisoni GB, Franco MG, Andreotti A, Ojala M, Pena S, Perales J, Chatterji S, Miret M, Tobiasz-Adamczyk B, Koskinen S, Frattura L, Leonardi M. Mapping SAGE questionnaire to the International Classification of Functioning, Disability and Health (ICF). Clin Psychol Psychother. 2014 May-Jun;21(3):199-203. doi: 10.1002/cpp.1857. Epub 2013 Jul 17. PubMed 23861299 ↗
  • Ayuso-Mateos JL, Miret M, Caballero FF, Olaya B, Haro JM, Kowal P, Chatterji S. Multi-country evaluation of affective experience: validation of an abbreviated version of the day reconstruction method in seven countries. PLoS One. 2013 Apr 23;8(4):e61534. doi: 10.1371/journal.pone.0061534. Print 2013. PubMed 23626697 ↗
  • Domenech-Abella J, Lara E, Rubio-Valera M, Olaya B, Moneta MV, Rico-Uribe LA, Ayuso-Mateos JL, Mundo J, Haro JM. Loneliness and depression in the elderly: the role of social network. Soc Psychiatry Psychiatr Epidemiol. 2017 Apr;52(4):381-390. doi: 10.1007/s00127-017-1339-3. Epub 2017 Feb 2. PubMed 28154893 ↗
  • Olaya B, Moneta MV, Miret M, Ayuso-Mateos JL, Haro JM. Epidemiology of panic attacks, panic disorder and the moderating role of age: Results from a population-based study. J Affect Disord. 2018 Dec 1;241:627-633. doi: 10.1016/j.jad.2018.08.069. Epub 2018 Aug 16. PubMed 30172214 ↗
  • Lara E, Caballero FF, Rico-Uribe LA, Olaya B, Haro JM, Ayuso-Mateos JL, Miret M. Are loneliness and social isolation associated with cognitive decline? Int J Geriatr Psychiatry. 2019 Nov;34(11):1613-1622. doi: 10.1002/gps.5174. Epub 2019 Jul 25. PubMed 31304639 ↗
  • Martin-Maria N, Caballero FF, Moreno-Agostino D, Olaya B, Haro JM, Ayuso-Mateos JL, Miret M. Relationship between subjective well-being and healthy lifestyle behaviours in older adults: a longitudinal study. Aging Ment Health. 2020 Apr;24(4):611-619. doi: 10.1080/13607863.2018.1548567. Epub 2018 Dec 28. PubMed 30590962 ↗
  • Cabello M, Borges G, Lara E, Olaya B, Martin-Maria N, Moreno-Agostino D, Miret M, Caballero FF, Haro JM, Ayuso-Mateos JL. The relationship between all-cause mortality and depression in different gender and age groups of the Spanish population. J Affect Disord. 2020 Apr 1;266:424-428. doi: 10.1016/j.jad.2020.01.162. Epub 2020 Jan 28. PubMed 32056909 ↗
  • Ayuso-Mateos JL, Morillo D, Haro JM, Olaya B, Lara E, Miret M. Changes in depression and suicidal ideation under severe lockdown restrictions during the first wave of the COVID-19 pandemic in Spain: a longitudinal study in the general population. Epidemiol Psychiatr Sci. 2021 Jun 2;30:e49. doi: 10.1017/S2045796021000408. PubMed 34074355 ↗
  • Lara E, Martin-Maria N, Miret M, Olaya B, Haro JM, Ayuso-Mateos JL. Is there a combined effect of depression and cognitive reserve on cognitive function? Findings from a population-based study. Psychol Health. 2022 Sep;37(9):1132-1147. doi: 10.1080/08870446.2021.1927030. Epub 2021 May 24. PubMed 34029134 ↗
  • Castelletti C, Lara E, Tobiasz-Adamczyk B, Koskinen S, Olaya B, Haro JM, Leonardi M, Kowal P, Chatterji S, Ayuso-Mateos JL, Miret M. Connecting and feeling: Associations between social factors and emotions in nine countries. Int J Psychol. 2023 Jun;58(3):282-291. doi: 10.1002/ijop.12892. Epub 2023 Feb 2. PubMed 36727409 ↗
  • Godino-Cruz J, Lara E, Caballero FF, Olaya B, Domenech-Abella J, Haro JM, Miret M, Ayuso-Mateos JL. Association between depression and all-cause, cardiovascular, and non-cardiovascular mortality in the Spanish population: a prospective cohort study. Arch Public Health. 2026 Jul 10. doi: 10.1186/s13690-026-02010-1. Online ahead of print. PubMed 42432735 ↗

Individual participant data

Plan to share: Undecided — A sharing plan description has to be still agreed between the different Principal Investigators

10

Updates

1 registry update since Sep 25, 2026
Status
Active, not recruiting→Completed
changed Oct 29, 2026
Results
Posted results revised
revised Oct 29, 2026
Sites
3 sites added, 3 sites removed
Show 3 added (3 Spain)
  • Fundació Sant Joan de Déu · Sant Boi de Llobregat, Spain
  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Madrid, Spain
  • Universidad Autónoma de Madrid · Madrid, Spain
Show 3 removed
  • Fundació Sant Joan de Déu · Sant Boi De Llobregat, Spain
  • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Madrid, Spain
  • Universidad Autónoma de Madrid · Madrid, Spain
Oct 29, 2026
Study completion
Dec 2026→Oct 2025 (actual)
Oct 29, 2026
Publications
Results publication added: Gabarrell-Pascuet A, Varga TV, Moneta MV, Ayuso-Mateos JL, Lara E, Olaya B, Haro JM, Domenech-Abella J. What factors explain the changes in major depressive di… PubMed 36806591 ↗; 21 more. 1 publication citing this study linked from PubMed
Oct 29, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • Changedother outcomeBefore Intensity of Subjective Perception of LonelinessNow LonelinessTime frame: Baseline
Oct 29, 2026
Sponsor
Collaborators added: Centro de Investigación Biomédica en Red de Salud Mental
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Active, not recruiting→Completed
    Posted results revised
    Publications Results publication added: Gabarrell-Pascuet A, Varga TV, Moneta MV, Ayuso-Mateos JL, Lara E, Olaya B, Haro JM, Domenech-Abella J. What factors explain the changes in major depressive di… PubMed 36806591 ↗; 21 more. 1 publication citing this study linked from PubMed
    3 sites added, 3 sites removed
    Show 3 added (3 Spain)
    • Fundació Sant Joan de Déu · Sant Boi de Llobregat, Spain
    • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Madrid, Spain
    • Universidad Autónoma de Madrid · Madrid, Spain
    Show 3 removed
    • Fundació Sant Joan de Déu · Sant Boi De Llobregat, Spain
    • Fundación de Investigación Biomédica - Hospital Universitario de La Princesa · Madrid, Spain
    • Universidad Autónoma de Madrid · Madrid, Spain
    Study completion Dec 2026→Oct 2025 (now actual)
    Secondary outcomes 1 edited
    What changed in the outcomes
    • Changedother outcomeBefore Intensity of Subjective Perception of LonelinessNow LonelinessTime frame: Baseline
    Sponsor Collaborators added: Centro de Investigación Biomédica en Red de Salud Mental
    + 7 other changes: identifiers, description, conditions, design details, arm descriptions, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03343886
Lead sponsor
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Collaborators
Fundació Sant Joan de Déu, Universidad Autonoma de Madrid, Centro de Investigación Biomédica en Red de Salud Mental
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Jul 2011
Primary completion
May 2012
Completion
Oct 2025
Results posted
Oct 15, 2024
Last update
Oct 29, 2026

Study contacts

Jose Luis Ayuso Mateos, MD, PhD
principal investigator · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Josep Maria Haro, MD, PhD
principal investigator · Fundació Sant Joan de Déu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Mental Disorders →

Other studies from this sponsor

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Start the discussion